Expression and Prognostic Significance of
Ki-67， Bcl-6， Bcl-2 and TEFM in Diffuse Large B
Cell Lymphoma

Abstract

Abstract: Objective： To explore the expression of Ki-67， Bcl-6， Bcl-2 and TEFM in diffuse large B cell lymphoma （DLBCL） and their relationship with the clinical characteristics and prognosis of patients. Methods： The expressions of Ki-67， Bcl-6， Bcl-2 and TEFM in 41 cases of DLBCL tissues and 42 cases of reactive proliferative lymphoid tissues were compared. The correlation between the expression levels of Ki-67， Bcl-6， Bcl-2 and TEFM and the clinicopathology of DLBCL was analyzed， and the prognostic factor of DLBCL patients were screened. Results： The expression level of Ki-67， Bcl-2 and Bcl-6 in DLBCL tissue were significantly higher than those in non-germinal central reactive proliferative lymphoid tissue，and the difference was statistically significant（P<0.05）. Ki-67 and TEFM protein expression levels were correlated with the primary site （P<0.05）. The 3-year survival rate of DLBCL patients was related to the age of patients， and the 3-year survival rate of patients aged ≥60 years was only 28.57%. Conclusion： Ki-67， Bcl-6 and Bcl-2 are highly expressed in DLBCL tissues. TEFM may have a synergistic effect on Ki-67， Bcl-6 and Bcl-2 in the progress of DLBCL. Ki-67， Bcl-6 and Bcl-2 can be used as important indicators of poor prognosis of DLBCL.

Key words: font-family:Times New Roman, ">diffuse large B cell lymphomafont-family:Times New Roman, ">, font-family:Times New Roman, "> Ki-67 expressionfont-family:Times New Roman, ">, font-family:Times New Roman, "> Bcl-6 expressionfont-family:Times New Roman, ">, font-family:Times New Roman, "> Bcl-2 expressionfont-family:Times New Roman, ">, font-family:Times New Roman, "> TEFM expression

CLC Number:

Sun Xiaomei, Mei Wen, He Bing, Luo Zhonggui, Sun Ruli, Xiong Wei, Zhao Yi.

Expression and Prognostic Significance of Ki-67， Bcl-6， Bcl-2 and TEFM in Diffuse Large B Cell Lymphoma [J]. Journal of Dali University, 2023, 8(2): 62-69.

References

〔1〕 SWERDLOW S H， CAMPO E， PILERI S A， et al. The 2016 Revision of the World Health Organization Classifi-cation of Lymphoid Neoplasms〔J〕. Blood，2016，127（20）：2375-2390.

〔2〕 LIU Y， BARTA S K. Diffuse Large B-Cell Lymphoma： 2019 Update on Diagnosis，Risk Stratification，and Treatment〔J〕. Am J Hematol，2019，94（5）：604-616.

〔3〕 ABRAMSON J S. Hitting Back at Lymphoma： How do Modern Diagnostics Identify High-Risk Diffuse Large B-Cell Lymphoma Subsets and Alter Treatment? 〔J〕. Cancer，2019，125（18）：3111-3120.

〔4〕 COIFFIER B， SARKOZY C. Diffuse Large B-Cell Lymphoma： R-CHOP Failure-What to Do? 〔J〕. Hematol Am Soc Hematol Educ Program，2016，2016（1）：366-378.

〔5〕 LEKAKIS L J， MOSKOWITZ C H. The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma in the Era of CAR-T Cell Therapy〔J〕. HemaSphere，2019，3（6）：e295.

〔6〕 AGARONYAN K， MOROZOV Y I， ANIKIN M， et al. Mitochondrial Biology. Replication-Transcription Switch in Human Mitochondria〔J〕. Science，2015，347（6221）：548-551.

〔7〕王唯斯，李翔宇，郝西琳，等.基于TCGA数据集分析脑胶质瘤中TEFM基因mRNA的表达及意义〔J〕.解放军医药杂志，2019，31（5）：15-21.

〔8〕 LI S Y，YOUNG K H，MEDEIROS L J. Diffuse Large B-Cell Lymphoma〔J〕.Pathology，2018，50（1）：74-87

〔9〕 CARO P， KISHAN A U， NORBERG E， et al. Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma〔J〕. Cancer Cell，2012，

22（4）：547-560.

〔10〕 POLYATSKIN I L， ARTEMYEVA A S， KRIVOLAPOV Y A. Revised WHO Ｃlassification of Ｔumors of Ｈemato-poietic and Ｌymphoid Ｔissues， 2017 （4th edition）：Ｌym-phoid Ｔumors〔J〕.Ａrkh Patol，2019，81（3）：59-65.

〔11〕 LIU Y， YANG Z Q， LAI P L， et al. BCL-6-Directed Follicular Helper T Cells Promote Vascular Inflammatory Injury in Diabetic Retinopathy〔J〕. Theranostics，2020，10（9）：4250-4264.

〔12〕 LI Z M， HUANG J J， XIA Y， et al. High Ki-67 Expression in Diffuse Large B-Cell Lymphoma Patients with Non-Germinal Center Subtype Indicates Limited Survival Benefit from R-CHOP Therapy〔J〕. Eur J Hae-matol， 2012，88（6）：510-517.

〔13〕 HASSELBLOM S， RIDELL B， SIGURDARDOTTIR M， et al. Low rather than High Ki-67 Protein Expression Is an Adverse Prognostic Factor in Diffuse Large B-Cell Lymphoma〔J〕. Leuk Lymphoma，2008，49（8）：1501-1509.

〔14〕 HE X， CHEN Z， FU T， et al. Ki-67 Is a Valuable Prognostic Predictor of Lymphoma But Its Utility Varies in Lymphoma Subtypes： Evidence from a Systematic Meta-Analysis〔J〕. BMC Cancer，2014，14：153.

〔15〕 BROYDE A， BOYCOV O， STRENOV Y， et al. Role and Prognostic Significance of the Ki-67 Index in Non-Hodgkin's Lymphoma〔J〕. Am J Hematol，2009，84（6）：338-343.

〔16〕 SALLES G， DE JONG D， XIE W L， et al. Prognostic Significance of Immunohistochemical Biomarkers in Diffuse Large B-Cell Lymphoma： A Study from the Lunenburg Lymphoma Biomarker Consortium〔J〕. Blood，2011，117（26）：7070-7078.

〔17〕 ZAIEM F， JERBI R， ALBANYAN O， et al. High Ki67 Proliferation Index But Ｎot Cell-of-Origin Subtypes Is Associated with Shorter Overall Survival in Diffuse Large B-Cell Lymphoma〔J〕. Avicenna J Med，2020，10（4）：241-248.

〔18〕周颖，赵瑜，薄剑，等.Ki-67在弥漫大B细胞淋巴瘤中的表达及临床意义〔J〕.中国实验血液学杂志，2013，21（5）：1162-1166.

〔19〕 TANG Y L， ZHOU Y， CHENG L L， et al. BCL2/Ki-67 Index Predict Survival in Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma〔J〕. Oncol Lett，2017，14（3）：3767-3773.

〔20〕 P?魤TRA?覶CU A M， ROTARU I， OLAR L， et al. The Prognostic Role of BCL-2， Ki67， C-MYC and P53 in Diffuse Large B-Cell Lymphoma〔J〕. Romanian J Morphol Embryol，2017，58（3）：837-843.

〔21〕吴红卫，黄蓉飞，戴小珍.Ki-67蛋白表达在弥漫大B细胞淋巴瘤预后判断中的意义〔J〕.四川医学，2014，35（6）：692-694.

〔22〕 ASHKENAZI A， FAIRBROTHER W J， LEVERSON J D， et al. From Basic Apoptosis Discoveries to Advanced Selective BCL-2 Family Inhibitors〔J〕. Nat Rev Drug Discov，2017，16（4）：273-284.

〔23〕 LI S Y， YOUNG K H， MEDEIROS L J. Diffuse Large B-Cell Lymphoma〔J〕. Pathology，2018，50（1）：74-87.

〔24〕于海，王慧，张娜，等.弥漫性大B细胞淋巴瘤中C-MYC蛋白表达与基因异常的相关性〔J〕.中华病理学杂志，2018，47（3）：172-175.

〔25〕韩永胜，薛永权，杨海燕，等.弥漫性大B细胞淋巴瘤免疫分型与分子遗传学异常的研究〔J〕. 中华医学遗传学杂志，2013，30（2）：143-147.

〔26〕李敏，刘翠苓，王小燕，等.bcl-2蛋白及分类模型在弥漫性大B细胞淋巴瘤中的预后意义〔J〕. 中华病理学杂志，2012，41（12）：813-817.

〔27〕蒋会勇，李慧灵，胡海，等.弥漫性大B细胞淋巴瘤t（14；18）易位及bcl-2基因扩增的检测〔J〕.中华病理学杂志，2007，36（2）：84-89.

〔28〕曾丽平，文亦磊，马韵，等.凋亡抑制基因bcl-2在弥漫性大B细胞淋巴瘤中的表达及其临床意义〔J〕. 中华病理学杂志，2011，40（6）：377-381.

〔29〕辛鹏亮，朱雄鹏，肖慧芳，等.弥漫性大B细胞淋巴瘤预后相关因素的初步探讨〔J〕.吉林医学，2014，35（32）：7184-7185.

〔30〕陈文婷，姚红霞，吴从明，等.MYC、BCL-2和BCL-6检测在弥漫性大B细胞淋巴瘤患者预后判断中的价值〔J〕.中国实验血液学杂志，2019，27（2）：452-457.

〔31〕 CI W M， POLO J M， MELNICK A. B-Cell Lymphoma 6 and the Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma〔J〕. Curr Opin Hematol，2008，15（4）：381-390.

〔32〕 BASSO K， DALLA-FAVERA R. Roles of BCL6 in Normal and Transformed Germinal Center B Cells〔J〕. Immunol Rev，2012，247（1）：172-183.

〔33〕 KUSAM S， VASANWALA F H， DENT A L. Transcri-ptional Repressor BCL-6 Immortalizes Germinal Center-Like B Cells in the Absence of P53 Function〔J〕. Oncog-ene，2004，23（3）：839-844.

〔34〕 SNUDERL M， KOLMAN O K， CHEN Y B， et al. B-Cell Lymphomas with Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms with Clinical and Pathologic Features Distinct from Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma〔J〕. Am J Surg Pathol，2010，34（3）：327-340.

〔35〕 FEI Z Y， WANG W S， LI S F， et al. High Expression of the TEFM Gene Predicts Poor Prognosis in Hepatocellular Carcinoma〔J〕. J Gastrointest Oncol，2020，11（6）：1291-1304.

〔36〕 WAN L X， WANG Y， ZHANG Z J， et al. Elevated TEFM Expression Promotes Growth and Metastasis through Activation of ROS/ERK Signaling in Hepatoce-llular Carcinoma〔J〕. Cell Death Dis，2021，12（4）：325.

[1]	Ma Yongjie, Li Weiqi, Wu Chunting, Huang Xinhui, Zhou Xinyu, Ya Fuli, . The Protective Effect and Mechanism of Panax notoginseng Saponins on ox-LDL-Induced Platelet Apoptosis [J]. Journal of Dali University, 2023, 8(2): 1-7.
[2]	Zhu Qianwei, Yang Hua, Qian Kai, Li Dan, Xia Conglong. Study on the Mechanism of Compound Longxuejie Capsules in Treating Coronary Heart Disease Based on Network Pharmacology and Molecular Docking [J]. Journal of Dali University, 2023, 8(2): 8-18.
[3]	He Siyue, Tang Ziyun, Liu Heng, Zhang Chenggui, Zhou Wen, Bi Ziying, Zhou Yue. Inhibition of K562 Cell Proliferation by p53 Protein Regulated by Periplaneta americana Extract CⅡ-3 [J]. Journal of Dali University, 2023, 8(2): 19-23.
[4]	Li Weiqian, Chen Yiming, Zhang Wenting, Su Yingzhen, Shuai Hongyan, Yu Xin. Bioinformatics-Ｂased Analysis and Screening of Differentially Expressed Genes in Pancreatic Cancer [J]. Journal of Dali University, 2023, 8(2): 24-30.
[5]	Cheng Mingjing, Yan Ping, Fan Yujuan, Zhao Weidong. Bioinformatic Analysis of Differentially Expressed Genes in the Patients Infected with Helicobacter pylori [J]. Journal of Dali University, 2023, 8(2): 31-35.
[6]	Yao Qiuyan, Wu Zesheng, Shi Rognjie, Yang Liwei. Analysis of Short-Term Prognostic Factors in Alcoholic Liver Disease-Related Acute-on-Chronic Liver Failure [J]. Journal of Dali University, 2023, 8(2): 36-41.
[7]	Song Qiuling, Dai Jiao. The Expression of Serum Progranulin in Patients with Graves Disease and Its Correlation with IL-17 and IL-10 [J]. Journal of Dali University, 2023, 8(2): 42-45.
[8]	Cheng Wei, Shi Haibin, Cun Xiangnong, Ai Kewei, Fan Jiaju, Yang Jiwu. A Comparative Study of the Clinical Efficacy of Endoscopic Thyroidectomy via the Thoracic-Breast Approach and Open Thyroidectomy [J]. Journal of Dali University, 2023, 8(2): 46-50.
[9]	Chen Huaqiu, Chen Xingyou, Wang Guangming. Study of the Distribution of High-Risk Human Papilloma Virus Subtypes in Liangshan Region， Sichuan Province [J]. Journal of Dali University, 2023, 8(2): 51-55.
[10]	Tian Tian, Yan Jing, Dai Jiao. Changes of MiR-1281 and MiR-122 in Peripheral Blood of DR Patients and Their Relationship with the Severity of Retinopathy [J]. Journal of Dali University, 2023, 8(2): 56-61.
[11]	Xia Wangxu, He Yongfang, Chen Xiaobo, Huang Chuanfen. The Value of Quantitative CT in Bone Mineral Density Measurement of Patients with Chronic Kidney Disease [J]. Journal of Dali University, 2023, 8(2): 70-73.
[12]	Dong Liwen, Wang Caihong, Zou Tuanbiao. Comparison of Three Detection Methods for Urinary Sediment [J]. Journal of Dali University, 2023, 8(2): 74-77.
[13]	Ni Zhaolin, Zuo Shunwu, Liu Hongyan, Ai Zhiqiong, Nong Luming, Zhao Qiufang, Wu Qiang. Epidemiological Characteristics and Trend Prediction of Influenza in Yuxi City from 2010 to 2019 [J]. Journal of Dali University, 2023, 8(2): 78-83.
[14]	Miao Zhifei, Huang Zhaodan, Chen Yanqing, Chang Yanping. Application of Drawing the Vascular Site Map under B-Ultrasound in Rope Ladder Puncture [J]. Journal of Dali University, 2023, 8(2): 84-87.
[15]	Zhu Xiaoli, Shi Tingting, Zhang Likun, Wei Yanni, Li Ting, Zhang Xiaoling. Application Analysis of Individualized Follow-Up Guidance Based on Network Platform in Patients with Basal Insulin [J]. Journal of Dali University, 2023, 8(2): 88-92.

Expression and Prognostic Significance of Ki-67， Bcl-6， Bcl-2 and TEFM in Diffuse Large B Cell Lymphoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments